Cargando…

Anchor-based classification and type-C inhibitors for tyrosine kinases

Tyrosine kinases regulate various biological processes and are drug targets for cancers. At present, the design of selective and anti-resistant inhibitors of kinases is an emergent task. Here, we inferred specific site-moiety maps containing two specific anchors to uncover a new binding pocket in th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hsu, Kai-Cheng, Sung, Tzu-Ying, Lin, Chih-Ta, Chiu, Yi-Yuan, Hsu, John T.-A., Hung, Hui-Chen, Sun, Chung-Ming, Barve, Indrajeet, Chen, Wen-Liang, Huang, Wen-Chien, Huang, Chin-Ting, Chen, Chun-Hwa, Yang, Jinn-Moon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4468516/ https://www.ncbi.nlm.nih.gov/pubmed/26077136 http://dx.doi.org/10.1038/srep10938

Ejemplares similares

Structures of Helicobacter pylori Shikimate Kinase Reveal a Selective Inhibitor-Induced-Fit Mechanism
por: Cheng, Wen-Chi, et al.
Publicado: (2012)

KIDFamMap: a database of kinase-inhibitor-disease family maps for kinase inhibitor selectivity and binding mechanisms
por: Chiu, Yi-Yuan, et al.
Publicado: (2013)

Zika Virus NS3 Protease Pharmacophore Anchor Model and Drug Discovery
por: Pathak, Nikhil, et al.
Publicado: (2020)

Targeting Spleen Tyrosine Kinase-Bruton's Tyrosine Kinase Axis for Immunologically Mediated Glomerulonephritis
por: Chen, Jin-Shuen, et al.
Publicado: (2014)

Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma
por: Wu, Chiao-En, et al.
Publicado: (2022)

Biomechanical comparison of different suture anchors used in rotator cuff repair surgery–all-suture anchors are equivalent to other suture anchors: a systematic review and network meta-analysis
por: Yang, Yi-Shiuan, et al.
Publicado: (2023)

Continuous epidermal growth factor receptor-tyrosine kinase inhibitor administration in primary lung adenocarcinoma patients harboring favorable mutations with controlled target lung tumors dose not hinder survival benefit despite small new lesions
por: Hsu, Ping-Chih, et al.
Publicado: (2016)

Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients
por: Chang, John Wen‐Cheng, et al.
Publicado: (2022)

Application of Radiomics in Prognosing Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis
por: Wang, Ting-Wei, et al.
Publicado: (2023)

Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation
por: Chen, Po-Yen, et al.
Publicado: (2021)

Protein Kinase RNA-Like Endoplasmic Reticulum Kinase-Mediated Bcl-2 Protein Phosphorylation Contributes to Evodiamine-Induced Apoptosis of Human Renal Cell Carcinoma Cells
por: Wu, Wen-Shin, et al.
Publicado: (2016)

Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan
por: Chang, John Wen‐Cheng, et al.
Publicado: (2022)

Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors
por: Huang, Chun-Ta, et al.
Publicado: (2023)

First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer
por: Huang, Allen Chung-Cheng, et al.
Publicado: (2021)

EGFR Tyrosine Kinase Inhibitor–Associated Interstitial Lung Disease During the Coronavirus Disease 2019 Pandemic
por: Chang, Hsu-Liang, et al.
Publicado: (2020)

Brain metastases in resected non-small cell lung cancer: The impact of different tyrosine kinase inhibitors
por: Yun, Po-Jen, et al.
Publicado: (2019)

Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitors
por: Hsu, Ping-Chih, et al.
Publicado: (2023)

Evaluating the Potential of Delta Radiomics for Assessing Tyrosine Kinase Inhibitor Treatment Response in Non-Small Cell Lung Cancer Patients
por: Wang, Ting-Wei, et al.
Publicado: (2023)

Emerging Roles of Calcium Signaling in the Development of Non-Alcoholic Fatty Liver Disease
por: Chen, Chien-Chih, et al.
Publicado: (2021)

A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma
por: Chen, Chieh-Lung, et al.
Publicado: (2023)

Poorer prognosis in Taiwanese female ever smokers with stage IV lung adenocarcinoma who were readministered a tyrosine kinase inhibitor
por: Yang, Chih-Jen, et al.
Publicado: (2016)

Epigenetic Deregulation of Protein Tyrosine Kinase 6 Promotes Carcinogenesis of Oral Squamous Cell Carcinoma
por: Hsieh, Yi-Ping, et al.
Publicado: (2022)

Space-related pharma-motifs for fast search of protein binding motifs and polypharmacological targets
por: Chiu, Yi-Yuan, et al.
Publicado: (2012)

Homopharma: A new concept for exploring the molecular binding mechanisms and drug repurposing
por: Chiu, Yi-Yuan, et al.
Publicado: (2014)

Semantic segmentation guided detector for segmentation, classification, and lesion mapping of acute ischemic stroke in MRI images
por: Wei, Yi-Chia, et al.
Publicado: (2022)

Inhibition of Bruton’s tyrosine kinase as a therapeutic strategy for chemoresistant oral squamous cell carcinoma and potential suppression of cancer stemness
por: Liu, Shao-Cheng, et al.
Publicado: (2021)

Culprits of PDAC resistance to gemcitabine and immune checkpoint inhibitor: Tumour microenvironment components
por: Hsu, Sheng-Kai, et al.
Publicado: (2022)

The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
por: Huang, Yen-Hsiang, et al.
Publicado: (2018)

High-Throughput Sorting of the Highest Producing Cell via a Transiently Protein-Anchored System
por: Chuang, Kuo-Hsiang, et al.
Publicado: (2014)

Pharmacophore anchor models of flaviviral NS3 proteases lead to drug repurposing for DENV infection
por: Pathak, Nikhil, et al.
Publicado: (2017)

Therapeutic impact of epidermal growth factor receptor tyrosine kinase inhibitor with various treatment combinations for advanced lung adenocarcinoma
por: Chen, Ying-Yi, et al.
Publicado: (2023)

Biocompatibility and Biological Performance Evaluation of Additive-Manufactured Bioabsorbable Iron-Based Porous Suture Anchor in a Rabbit Model
por: Tai, Chien-Cheng, et al.
Publicado: (2021)

Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification
por: Ke, Yi-Yu, et al.
Publicado: (2015)

The Combination of Sleep Disorders and Depression Significantly Increases Cancer Risk: A Nationwide Large-Scale Population-Based Study
por: Hsu, Fang-Chin, et al.
Publicado: (2022)

Comparison of the effects of the three major tyrosine kinase inhibitors as first-line therapy for non-small-cell lung cancer harboring epidermal growth factor receptor mutations
por: Tu, Chih-Yen, et al.
Publicado: (2018)

Pathway-based Screening Strategy for Multitarget Inhibitors of Diverse Proteins in Metabolic Pathways
por: Hsu, Kai-Cheng, et al.
Publicado: (2013)

Elevated Surgical Pleth Index at the End of Surgery Is Associated with Postoperative Moderate-to-Severe Pain: A Systematic Review and Meta-Analysis
por: Hung, Kuo-Chuan, et al.
Publicado: (2022)

Baseline, Trend, and Normalization of Carcinoembryonic Antigen as Prognostic Factors in Epidermal Growth Factor Receptor-Mutant Nonsmall Cell Lung Cancer Patients Treated With First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Chen, Yu-Mu, et al.
Publicado: (2015)

Early serum tumor marker levels after fourteen days of tyrosine kinase inhibitor targeted therapy predicts outcomes in patients with advanced lung adenocarcinoma
por: Chen, Hung-Jen, et al.
Publicado: (2020)

Reactivation of Hepatitis B Virus in Lung Cancer Patients Receiving Tyrosine Kinase Inhibitor Treatment
por: Lee, Po-Hsin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_miau1bpf6mod0rkj9qmgm0rtba